[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 441,539,232
  • Shares Outstanding, K 1,766,793
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,332 M
  • EBITDA $ 24,318 M
  • 60-Month Beta 0.30
  • Price/Sales 7.30
  • Price/Cash Flow 16.69
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 28.91% (+0.02%)
  • Historical Volatility 32.95%
  • IV Percentile 74%
  • IV Rank 62.08%
  • IV High 35.30% on 04/27/26
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 7) 5.65 (2.28%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 22,660
  • Volume Avg (30-Day) 17,039
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 262,074
  • Open Int (30-Day) 250,071
  • Expected Range 242.43 to 253.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.71
  • Number of Estimates 1
  • High Estimate $3.71
  • Low Estimate $3.71
  • Prior Year $2.97
  • Growth Rate Est. (year over year) +24.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
215.37 +15.19%
on 06/18/26
261.64 -5.18%
on 07/02/26
+23.13 (+10.28%)
since 06/10/26
3-Month
190.75 +30.06%
on 04/29/26
261.64 -5.18%
on 07/02/26
+40.14 (+19.30%)
since 04/10/26
52-Week
184.63 +34.37%
on 07/21/25
261.64 -5.18%
on 07/02/26
+53.08 (+27.22%)
since 07/10/25

Most Recent Stories

More News
5 Dividend Kings to Buy in July with Irristable Value and Yield

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

HRL : 24.73 (+1.64%)
ABT : 93.93 (-0.50%)
ORLY : 86.28 (+1.36%)
LOW : 211.63 (-0.64%)
SWK : 88.22 (+1.61%)
AZO : 3,072.64 (+2.07%)
PG : 147.04 (+0.13%)
GPC : 125.62 (+1.09%)
ABBV : 248.08 (-0.73%)
AbbVie Earnings Preview: What to Expect

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

XLV : 160.84 (-0.82%)
$SPX : 7,575.39 (+0.42%)
APOG : 38.82 (-0.10%)
ABBV : 248.08 (-0.73%)
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

APGE : 133.65 (+0.06%)
LLY : 1,188.58 (-2.33%)
ABBV : 248.08 (-0.73%)
Abivax: Wall Street Catches Up to the Data

Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional demand....

ABBV : 248.08 (-0.73%)
ABVX : 139.90 (-0.60%)
3 Market-Beating Stocks Worth Investigating

3 Market-Beating Stocks Worth Investigating

WTS : 352.36 (+1.25%)
SFM : 80.86 (+0.60%)
ABBV : 248.08 (-0.73%)
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill. , July 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination...

ABBV : 248.08 (-0.73%)
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

ABBV : 248.08 (-0.73%)
Wall Street Says to Buy These 3 Dividend Aristocrats

Analysts are generally favorable when it comes to companies that boast at least a quarter-century of uninterrupted dividend growth, but these are some of their highest-rated names.

TGT : 135.14 (+2.17%)
ABT : 93.93 (-0.50%)
ABBV : 248.08 (-0.73%)
WMT : 113.90 (+1.51%)
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NORTH CHICAGO, Ill. , June 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging...

ABBV : 248.08 (-0.73%)
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

NORTH CHICAGO, Ill. , June 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...

ABBV : 248.08 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 258.09
2nd Resistance Point 254.88
1st Resistance Point 251.48
Last Price 248.08
1st Support Level 244.87
2nd Support Level 241.65
3rd Support Level 238.25

See More

52-Week High 261.64
Last Price 248.08
Fibonacci 61.8% 232.22
Fibonacci 50% 223.13
Fibonacci 38.2% 214.05
52-Week Low 184.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.